Annual report
4583.TEDINET S100XUJT
Period2025-01-01 → 2025-12-31
Filed2026-03-27
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 76
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥593m | 2025-01-01 → 2025-12-31 | Standalone | Net sales |
| Revenue | ¥781m | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥682m | 2023-01-01 → 2023-12-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥631m | 2022-01-01 → 2022-12-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥713m | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥980m | 2025-01-01 → 2025-12-31 | Standalone | Operating income |
| Operating income | −¥1.0bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Ordinary income | −¥989m | 2025-01-01 → 2025-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.0bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.2bn | 2023-01-01 → 2023-12-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.2bn | 2022-01-01 → 2022-12-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.3bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥980m | 2025-01-01 → 2025-12-31 | Standalone | Income before income taxes |
| Profit before tax | −¥1.0bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Net income | −¥983m | 2025-01-01 → 2025-12-31 | Standalone | Profit loss |
| Net income | −¥1.0bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | −¥1.2bn | 2023-01-01 → 2023-12-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.2bn | 2022-01-01 → 2022-12-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.5bn | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.7bn | at 2025-12-31 | Standalone | Assets |
| Total assets | ¥2.5bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥1.8bn | at 2023-12-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.2bn | at 2022-12-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.3bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥605m | at 2025-12-31 | Standalone | Liabilities |
| Total liabilities | ¥549m | at 2024-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.1bn | at 2025-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.9bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.2bn | at 2023-12-31v | Standalone | Net assets |
| Net assets / equity | ¥1.8bn | at 2022-12-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.9bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2025-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.1bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.2bn | at 2025-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2024-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2023-12-31v | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.7bn | at 2022-12-31v | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.8bn | at 2021-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥936m | 2025-01-01 → 2025-12-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.0bn | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.1bn | 2023-01-01 → 2023-12-31v | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.2bn | 2022-01-01 → 2022-12-31v | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.1bn | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥55m | 2025-01-01 → 2025-12-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥173,000 | 2023-01-01 → 2023-12-31v | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥35m | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥133m | 2025-01-01 → 2025-12-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.7bn | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥667m | 2023-01-01 → 2023-12-31v | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2022-01-01 → 2022-12-31v | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥271m | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-14.47 | 2025-01-01 → 2025-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-17.54 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-24.62 | 2023-01-01 → 2023-12-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-28.26 | 2022-01-01 → 2022-12-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-36.74 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥16.18 | at 2025-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥28.53 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥21.66 | at 2023-12-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥36.7 | at 2022-12-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥45.55 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 64.1% | at 2025-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.4% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.1% | at 2023-12-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.2% | at 2022-12-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.4% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 68,453,800 | at 2025-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 66,969,000 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 52,640,200 | at 2023-12-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 48,423,500 | at 2022-12-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 40,781,500 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 49 | at 2025-12-31 | Standalone | Number of employees |
| Employees | 47 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 51 | at 2023-12-31v | Standalone | Number of employees |
| Employees | 49 | at 2022-12-31v | Standalone | Number of employees |
| Employees | 49 | at 2021-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 22
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-12-31 | −¥559m |
| Drug Discovery And Developmentreportable segment | segment profit | 2025-01-01 → 2025-12-31 | −¥777m |
| Drug Discovery Supportreportable segment | depreciation | 2025-01-01 → 2025-12-31 | ¥4m |
| Drug Discovery Supportreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥593m |
| Drug Discovery Supportreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥593m |
| Drug Discovery Supportreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥356m |
| —segment total | employees | at 2025-12-31 | 39 pure |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-01-01 → 2025-12-31 | ¥4m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-12-31 | ¥593m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-12-31 | ¥593m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-12-31 | −¥421m |
| Reconciling Itemsreconciling | depreciation | 2024-01-01 → 2024-12-31 | ¥1m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | −¥527m |
| Drug Discovery And Developmentreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥203m |
| Drug Discovery And Developmentreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥203m |
| Drug Discovery And Developmentreportable segment | segment profit | 2024-01-01 → 2024-12-31 | −¥814m |
| Drug Discovery Supportreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥578m |
| Drug Discovery Supportreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥578m |
| Drug Discovery Supportreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥310m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-01-01 → 2024-12-31 | ¥781m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-01-01 → 2024-12-31 | ¥781m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-01-01 → 2024-12-31 | −¥504m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 832
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes share options etc financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes tax effect accounting financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes business combinations financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes asset retirement obligations financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes revenue recognition financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes segment information etc financial statements (text) | CurrentYearDuration | Text · Plus | |
| Description of reportable segments (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Explanation of measurements of sales profit loss asset liability and other items for each reportable segment (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YearDuration_NonConsolidatedMember | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Information for each product or service (text) | Prior1YearDuration_NonConsolidatedMember | Text · Plus | |
| Revenues from external customers information for each region (text) | Prior1YearDuration_NonConsolidatedMember | Text · Plus | |
| Property plant and equipment information for each region (text) | Prior1YearDuration_NonConsolidatedMember | Text · Plus | |
| Information for each of main customers (text) | Prior1YearDuration_NonConsolidatedMember | Text · Plus | |
| Information for each product or service (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Revenues from external customers information for each region (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Property plant and equipment information for each region (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Information for each of main customers (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Notes related parties financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes per share information financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes significant events after reporting period financial statements (text) | CurrentYearDuration | Text · Plus | |
| Annexed detailed schedule of property plant and equipment etc (text) | CurrentYearDuration | Text · Plus | |
| Annexed detailed schedule of corporate bonds financial statements (text) | CurrentYearDuration | Text · Plus | |
| Annexed detailed schedule of borrowings financial statements (text) | CurrentYearDuration | Text · Plus | |
| Annexed detailed schedule of provisions (text) | CurrentYearDuration | Text · Plus | |
| Annexed detailed schedule of asset retirement obligations financial statements (text) | CurrentYearDuration | Text · Plus | |
| Components of major assets and liabilities (text) | CurrentYearDuration | Text · Plus | |
| Other information financial statements etc (text) | CurrentYearDuration | Text · Plus | |
| Overview of operational procedures for shares (text) | FilingDateInstant | Text · Plus | |
| Information about parent company etc of reporting company (text) | FilingDateInstant | Text · Plus | |
| Other reference information (text) | FilingDateInstant | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |